76870-09-2

Basic information

• Product Name: AKOS BC-1990
• Synonyms: AKOS BC-1990;CHEMBRDG-BB 6570475;4-(2-MORPHOLIN-4-YL-2-OXOETHOXY)ANILINE;UKRORGSYN-BB BBV-099900;[4-(2-morpholin-4-yl-2-oxoethoxy)phenyl]amine;4-(2-morpholin-4-yl-2-oxoethoxy)aniline(SALTDATA: FREE);2-(4-aminophenoxy)-1-morpholin-4-ylethanone;2-(4-aminophenoxy)-1-morpholin-4-yl-ethanone
• CAS NO: 76870-09-2
• Molecular Formula: C₁₂H₁₆N₂O₃
• Molecular Weight: 236.269
• Mol File: 76870-09-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 479.7°C at 760 mmHg
• Flash Point: 243.9°C
• Appearance: /
• Density: 1.24g/cm³
• Vapor Pressure: 2.31E-09mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: AKOS BC-1990(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BC-1990(76870-09-2)
• EPA Substance Registry System: AKOS BC-1990(76870-09-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 76870-09-2(Hazardous Substances Data)

Usage

General Description

AKOS BC-1990 is a chemical compound with the molecular formula C18H20O6. It is a synthetic intermediate that is used in the production of pharmaceuticals and other organic compounds. This chemical is a solid at room temperature and has a molecular weight of 332.34 g/mol. It is also known by its chemical name, 6,7-dimethoxy-4,5,6,7-tetrahydro-1-benzofuran-3-one, and it is characterized by its aromatic and oxygen-containing functional groups. AKOS BC-1990 may be used as a building block in organic synthesis and as a research chemical in various laboratory experiments.

InChI:InChI=1/C12H16N2O3/c13-10-1-3-11(4-2-10)17-9-12(15)14-5-7-16-8-6-14/h1-4H,5-9,13H2

Upstream product

• 100-02-7 4-nitro-phenol 
• 19076-89-2 ethyl 4-nitrophenoxyacetate 
• 20142-88-5 2-(4-nitrophenoxy)acetyl chloride 
• 19786-48-2 methyl 2-(4-nitrophenoxy)acetate 
• 1798-11-4 4-nitrophenoxyacetic acid 
• 50508-33-3 1-(morpholin-4-yl)-2-(4-nitrophenoxy)ethanone 

Downstream Products

• 110506-65-5 2-(4-Isothiocyanato-phenoxy)-1-morpholin-4-yl-ethanone 

Relevant articles and documents

Diaryl urea compound as well as preparation method and pharmaceutical application thereof

The invention belongs to the field of medicinal chemistry, and discloses a novel diarylurea compound as shown in a formula (I), physiologically acceptable salts, solvates and crystal forms of the novel diarylurea compound, a preparation method of the comp

JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma

JAK3 is predominantly expressed in hematopoietic cells and has been a promising therapeutic target for the treatment of B-cell lymphoma. In this study, a new class of thieno[3,2-d]pyrimidines harboring acrylamide pharmacophore were synthesized as potent covalent JAK3 inhibitors (IC50 50 values of 1.9 nM and 1.8 nM, respectively. Furthermore, compared with the reference agents, Spebrutinib and Ibrutinib, 9a not only demonstrated enhanced antiproliferative activity against B lymphoma cells, but also showed very weak proliferative inhibition against normal peripheral blood mononuclear cells (PBMCs) at a concentration of 20 μM. Analysis of the mechanism revealed that 9a could induce the obvious apoptosis in B lymphoma cells and prevent JAK3-STAT3 cascade as well as BTK pathway. Taken together, 9a may be served as a potential new JAK3 inhibitor for the treatment of B-cell lymphoma.

Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma

The BTK and JAK3 receptor tyrosine kinases are two validated and therapeutically amenable targets in the treatment of B-cell lymphomas. Here we report the identification of several classes of pyrimidine derivatives as potent BTK and JAK3 dual inhibitors.